Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients - CASE-J

EBM Collaborating Research Center in Kyoto University0 个研究点目标入组 4,000 人开始时间: 2005年10月30日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.SBP ≥200 mmHg or DBP ≥120 mmHg in a sitting position 2.Type I diabetes mellitus 3.History of myocardial infarction or cerebrovascular accidents within 6 months prior to the screening 4.PTCA or CABG done within 6 months of screening or scheduled 5.Current treatment for congestive cardiac failure (NYHA functional class II or severer) or ejection fraction <40% 6.Coronary artery disease requiring beta blocker or calcium channel blocker 7.Atrial fibrillation or atrial flutter 8.Renal dysfunction (serum creatinine ≥3 mg/dl) 9.Hepatic dysfunction (AST and/or ALT ≥100 IU/l) 10.A history of malignant tumor within 5 years of enrollment or suspected 11.Contraindication for candesartan cilexetil or amlodipine besilate 12.Pregnancy, possible pregnancy, or plan to conceive a child within 5 years of enrollment 13.Not suited to the clinical trail as judged by a collaborating physician 14.Inability to give informed consent

发起方

EBM Collaborating Research Center in Kyoto University